“New York Biotech Stock To Soar 997% As Stem Cell Market Explodes In 2012”

Sniffing out the stock teased by Manny Backus for his Penny Stocks Guru Service

By xiexgp@gmail.com, June 28, 2012

We’ve seen folks ask about Manny Backus services before — he’s published a few different alert services and newsletters in the past, most of them focused, as far as I can tell, on short-term trading. We haven’t written about any of them before because he hasn’t actually teased anything very specific in terms of a trading strategy or a particular stock … but that ends today.

Because he’s now pitching what looks like a new service (new to me, at least) called Penny Stocks Guru … and in urging you to sign up, he’s teasing a specific little biotech company that he thinks will go up by 997%.

Here’s the intro:

“‘This has never been accomplished before… Now we have done it.’
~ Eduardo Marban, Director, Cedars-Sinai Heart Institute ~

“New York Biotech Stock To Soar 997% As Stem Cell Market Explodes In 2012

“Scientists from Cedars-Sinai Heart Institute and Johns Hopkins University discover medical miracle to beat the number one disease killing Americans… AND… catapult this tiny company’s stock to all-time highs as news spreads
like wildfire. Investors who act fast could bank record returns…”

So it’s easy to see why so many readers have sent in questions about this particular ad — and, frankly, why it also piqued my curiosity. We also will keep in our minds that the broad promise of stem cells has made far more headlines than it has fortunes so far, and that past teaser picks of stem cell companies that will revolutionize the world have not generally been barn-burners in recent years.

Still, some have experienced big temporary gains on the back of headline breakthroughs, and some have continued growing and advancing the science with an eye to eventual products and revenue, so maybe someone will make a bunch of money on stem cells in the decade to come (instead of just making money by selling you the promise of stem cells). Will this little stock that Backus is teasing be the one?

Well, let’s dig into his clues and see what he’s talking about so you can make that call for yourself.

First is the general bit about stem cells and a treatment for heart disease, which is what that “never been accomplished before” quote above is about:

“New research continues to propel the industry forward. Positioning one little-known biotech company for explosive growth over the coming months.

“In late 2011, scientists from Cedars-Sinai Heart Institute and Johns Hopkins University, reported the results of a recent clinical trial. Which could help millions of heart attack patients recover and live a full life.

“Cardiac stem cells were harvested from healthy heart tissue of people who suffered a heart attack. The stem cells were grown in a lab and given back to patients.

“Those who received the treatment showed significant reduction in scar tissue on the heart muscle.

“The muscle tissue regenerated.

“Which has never been seen before in any clinical trials or studies….

“Breakthroughs such as this fuel growth across the stem cell market. Conservative estimates show the market may rise to over $1 billion in 2012.”

Which all leads you to the assumption that he thinks we should buy the company behind this heart treatment breakthrough — but that’s not the case, that particular study was funded with public money and is very early-stage, the patent on this treatment is claimed by Johns Hopkins, which is where Dr. Marban worked before moving cross-country to Cedars-Sinai, and it’s licensed to a tiny company that’s partly owned by Marban and run by his wife but is not publicly traded (the company’s name is Capricor, in case you’re interested in that end of the story).

So no, we’re not being told to invest in this particular breakthrough — rather, this sets up as a more generic investment in stem cells as a trend through a different little company that is publicly traded. Here are some specific clues about the “New York Biotech” that he’s apparently recommending:

“At the forefront of stem cell medicine is a small New York-based biotech.

“Our research indicates this company’s stock is about to take off. By as much as 997%. Allowing investors who get in now to book spectacular gains.

“Let me explain why…

“Right now, this company’s stock pays out 13% in annual dividends. You can profit from both potential appreciation and quarterly dividend checks. Yet the stock is overlooked. Trading at about 22% below its book value.

“In other words, this stock is a bargain.

“Sounds good… but… that’s not even half the story.

“This company engages in the development and manufacture of cellular therapies for oncology, immunology and regenerative medicines. It also is a leader in the collection, processing and storage of adult stem cells.

“Which means, this company’s cellular therapies and stem cell banking services play a crucial role in the industry at large. Leading medical institutions (like Cedars-Sinai and Johns Hopkins) depend upon this company’s research, therapies and stem cell storage facilities to further their own research capabilities.”

13% annual dividends? For a stem cell company? Trading below book value? There must be a story here, though it’s probably an odd one.

Some more clues to make sure we feed the Thinkolator fully?

“This company has eight adult stem cell collection centers across six states. Ongoing studies on adult stem cell applications and manufacturing.

“Plus international interests in a China-based pharmaceuticals manufacturing company.

“The revenues of this company more than doubled from $32 million to $69 million.

“A larger number of conservative investors are now investing in the stem cell market.

“Fueling the inevitable growth in this company’s stock price.

“In August of 2011, this company was…

“Awarded Almost $1.7-Million From The U.S. Department Of Defense”

And we get some chatter about how the Vatican just loves this company — that’s because of that “adult” word in the paragraphs above, the Pontiff and his potentates don’t like embryonic stem cells one bit but they have apparently endorsed the use of adult stem cells (meaning, stem cells derived from adult tissue — not from embryos, which are the “natural” and more well-known source for stem cells — if you don’t know anything about this science, the basic backdrop is that stem cells are cells that can easily become any kind of bodily tissue, which makes them natural candidates for helping to replace damaged or diseased tissue in the body, and early undefined embryos are entirely made up of these kinds of cells — but there has also been substantial progress made in creating stem cells from less-ethically-complicated adult tissue).

So who is it? Well, let’s rev up the Thinkolator on this one — chop up those clues and feed ’em in, and out the other end comes a shiny little answer: Neostem (NBS)

Which is indeed a tiny little biotech in New York, and they do have interest in a Chinese pharma company (though they’ve agreed to sell it, a deal that they think will close by the end of the year). And, actually, they do also have a heart disease therapy that they want to advance to Phase II trials and which also, like the one from Dr. Marban mentioned above, aims to inject stem cells into the heart to repair damaged tissue.

And yes, they do match perfectly on the clues — they do have an agreement with the Vatican, they have done work under grants from the Defense Department and other agencies (their latest is a relatively small deal to study radiation treatment, for a division of the NIH, but they also got funding from the DOD to research osteoporosis treatment last year).

This is an interesting company, the kind that typically comes to the attention of stock promoters and microcap fans — because they do have cash on the books, they do have a real business that’s easy to pitch to investors even if it’s far from being profitable, and they are, from a quick look at the balance sheet and their deal to sell off Suzhou Erye Pharmaceutical, trading at less than book value. From what I read about the deal to sell off Suzhou Erye they’ll be basically getting rid of Suzhou’s debt ($37 million) and getting $12 million in cash, so the net impact on the balance sheet is substantial for a company with a market cap of only $60 million — they’ll be going from an enterprise value of $80 million to an enterprise value of $40 million or so when the deal goes through. Which won’t show up in conventional measures like Price/earnings or EBITDA metrics, since they don’t and won’t have any earnings, but it does mean they’ll be a bit more concentrated on their core business and will have more cash to use in that business.

Assuming, of course, that they haven’t already spent all that cash before the end of the year. Biotech research and FDA clinical trials are horrifically expensive, and it’s going to be a long, long time before Neostem makes any money. I presume that a lot of the incoming revenue for Neostem probably came from the Chinese subsidiary, too, since that was a real business (albeit a challenged one recently — they manufacture generic drugs and apparently have been hit by cost controls and other regulatory pressure in China).

None of this is new, of course — the company has publicly stated their goals of divesting their Chinese subsidiary and dropping their lower-level stem cell services businesses in order to focus on developing drugs. The capability to develop those drugs came in last year thanks to their acquisitions of PCT (a stem cell manufacturer and cord-blood banker and controller of Athelos, an immunotherapy researcher) and Amorcyte (which brought that heart stem cell therapy through Phase I). So this is clearly a company in transition, with the immediate catalyst now being the Phase II trial for AMR-001 (that heart injection), which is supposed to be enrolling now and generating some data by late next year. These things always take longer than expected, but it does seem to be underway.

And Neostem is not the only one going through with stem cell related therapies related to heart attacks — rebuilding damaged heart tissue is, after all, one of the obvious applications of stem cells and it has been studied for many years. Longtime readers might remember the frantic teasers for Cytori Therapeutics (CYTX), which was not specifically developing their own heart disease cure but was teased as a play on this “single shot” treatment for damaged heart tissue. That stock has bounced around between two dollars and eight dollars a share over the intervening years as promise led to peril and back to promise, so that’s a good chart to look at to remind you of the fashion-driven, news-driven, and surprising moves these kinds of stocks can take even if they do seem to have a legitimate business.

But even beyond that, there are plenty of drugs in clinical trials for stem cell-based repair of heart tissue — and presumably each one has slightly different techniques or technologies that are patented or patentable, but I have no idea specifically what the differences are. There are also a lot of very sketchy-looking companies that are trying to peddle stem cell heart treatments now (the FDA-approved trials from various companies for this treatment started in 2009, but it’s been studied and tested in various forms for far longer, with impressive bone marrow stem-cells-to-heart results from the late 1990s in animals, and folks have been pushing ahead with these treatments overseas with less caution than the FDA), so it’s a confusing maze and there are companies actively selling devices and technologies and treatments that are approved in the EU or in Asia but that aren’t FDA-approved.

The basic idea of AMR-001 is not too different from what has been researched for years, taking bone marrow from the patient and extracting specific stem cells from that marrow, and then injecting that into the heart for delivery to the right part of the muscle. And if you want more than that, you’ll have to researchify it on your own because it makes my brain hurt. Do keep in mind that although the drug is “phase II ready” and they’re apparently enrolling patients for that trial, Phase I was actually completed way back in 2008 … so this hasn’t exactly been moving with lightning speed so far. And if you look at the historical accomplishments claimed by Neostem on their website, almost every year (including this year) there’s an entry for “raised $XX million.”

The stock is right around 46 cents a share as I type this, and has been in a steady decline over the last year … or really, if you take the longer view, it’s been in a steady decline for 12 years. It peaked at around $400 (yes, Four Hundred Dollars a share) in 2000 during the tech boom that took a lot of biotech stocks up with it, and fell to $25 within a year or so as it started what has been a long, slow descent over time into penny stock territory.

If you want to get an idea of what Neostem’s products and plans are, they do have a nice little one-page fact sheet here and a longer presentation here. So go forth, do your due diligence, and let us know what you think — the stock is up a bit in recent weeks because investors are happy with that planned Chinese divestiture, and it may well get a bump from Backus because he’s got access to an awful lot of email addresses in his various services, but I imagine it will be a while before we get any fundamental news — though since this is a biotech stock trying to move forward in clinical trials, the one thing we can be really certain of is the fact that they’ll eventually need a lot more cash or a partnership deal to pay for that research, so that could certainly impact their share price well before we know anything about their Phase II trial. They’re also revving up their investor relations engine, including presentations at a bunch of conferences this Spring and Summer, so the increased attention might well help the stock for at least a little while. The revenue for the foreseeable future will come from the PCT division, which has worked for dozens of cell therapy companies and processed a lot of stem cell treatments — they were even involved early on with Dendreon in processing/manufacturing Provenge as that was going through trials, though I don’t think they are now.

If the stock goes up 997% this year, well, I’ll eat my hat — but that doesn’t mean it can’t go up considerably over the next several years if their results are good and they time their fundraising (or partnership deals) well. The same could likely be said for many other stem cell-focused biotechs, and as I said I have no idea how unique this product might be, but Neostem is, at least, in pretty decent financial shape for the rest of the year if the sale of their Chinese division goes through and that division brings its debt along as expected.

P.S. About that dividend thing? Neostem does not pay a dividend, though I continue to occasionally see notes or older summaries that indicate they do or did pay a dividend, and a pretty big one at that, so that may be where Backus is getting his 13% yield from. Those must reference either their convertible preferred stock, which has now all been redeemed, or some past special dividend that they don’t talk about much — though frankly, the most likely source for the phantom NBS dividend data that I’ve seen in the past at places like Morningstar and Yahoo Finance is probably just a typo or glitch. Given their capital requirements and their focus on drug development, it would be shocking if they paid a dividend in the near future — since the other clues matched precisely I stopped looking for more info on this illusory dividend, but if you know the story on that feel free to shout it out with a comment below.

Related Gumshoe Articles

What is the “the Holy Grail of breath testing” from Penny Stocks Guru? Will the company behind it quadruple your money?

Manny Backus says "This tiny U.S. company has what top doctors call 'the Holy Grail' in stopping cancer, heart disease, diabetes, even obesity"

12 Comments Read More

Leave a Reply

35 Comments on "“New York Biotech Stock To Soar 997% As Stem Cell Market Explodes In 2012”"

avatar

Stan Blumin
Guest
0
Stan Blumin
June 28, 2012 3:37 pm

Sounds like a company whose main business is selling stock.

Edward Maddox
Guest
0
Edward Maddox
June 28, 2012 5:05 pm

This sounds pretty iffy, but I will do some watching and waiting and see if anyone takes the Penny Stocks Guru newsletter and starts to buy NBS. If it really can begin to pump up, I’ll risk a few 25 cent pieces on it.

shoeless
Guest
0
shoeless
June 28, 2012 5:40 pm
The two stem cell scompanies I’m pretty happy owning is ACTC doing stem cell injections into the back of the eye for reversing degenerative eye disease which is the only FDA stem cell approved on going study I know of. And PSTI which I like the best, saved a child’s life with two stem cell injections who had been in a complete state of failure after two bone marrow transplants. The injections turned the cell death in reverse and is still doing well. Also, they have a stem cell manufacturing process which is prolific, cheap ,and creates cells that are… Read more »
fxtr
Guest
0
FXTR
June 29, 2012 4:49 am

Very interesting – thanks shoeless!

Lewis Nicholson
Guest
0
Lewis Nicholson
June 28, 2012 9:04 pm

I’m with you Travis, the more I read all this edge breaking cliff hanging…just about there research companies….. well it makes my brain hurt too
I’m just about to go fishing

Edward Maddox
Guest
0
Edward Maddox
June 28, 2012 9:51 pm

Shoeless,

I bought some CUR about one month ago paying $0.95 and it has dropped slowly ever since. Closed today at $0.86. This mostly the stinky market that we find ourselves in, but I have a few stocks that can go up even on the bad days for the DOW, etc.

JB
Guest
0
JB
June 29, 2012 3:19 pm
Well…I have posted a few times that I am somewhat lost. I don’t have any stocks to speak of except for some mutual funds that were given to me years ago by a family member. I keep thinking I want to get into stocks but I have an ongoing problem. I converted my retirement funds into a self directed 401K. I am now making between 12%-15% return and this is guaranteed and in my opinion risk free. With that in mind I am having a hard time buying into stocks. If I did right now it would probably be some… Read more »
Travis Johnson, Stock Gumshoe
Admin
4429
June 29, 2012 5:28 pm

If I got a guaranteed 15 percent return and didn’t feel the need to diversify, I’d never touch stocks except for fun and gambling. Of course, opinions about what is “guaranteed” differ.

Edward Maddox
Guest
0
Edward Maddox
June 29, 2012 8:54 pm
Right On Travis! 12% or 15% with reinvestment of the same, can hardly be beat by any but the most careful and shrewd of stock investors. All it takes is the patience to stay with it and a good bit of time. I could wish for more time, so I have to do things that are not really long term unless I want to make my heirs wealthier than I can be. How old does one have to be to not have a “long term” future? You could ask if you are really curious. LOL or whatever that shorthand thing… Read more »
2late
Member
0
2late
July 3, 2012 3:38 pm

I’m a newbie to gumshoe, but also would like to know more about the guaranteed 12-15%. This would definitely be a rarity in today’s market or investments. If you have it, stick with it, at least until times change in maybe a few years. Don’t know where you would beat the return without getting into more risky investments like short term holding and trading options, which is not easy and more risk inherent. Look forward to some feedback on your current holdings and investments.

frenchi55
Member
0
frenchi55
July 9, 2012 2:41 pm

look at psec at !0% dividend paid every month

ray hane
Guest
0
ray hane
August 5, 2012 11:23 pm

Explain how you converted your 401 exactly into what? rrhane02@moreheadstate.edu
ray

DanDC
Guest
0
DanDC
June 29, 2012 9:35 pm

JB
Darn what’s the guaranteed 12to 15% I’m ready to sign up for that one.

Franklin White
Guest
0
Franklin White
June 30, 2012 6:07 pm

Travis, I’m continuously impressed with your research and your articles. There, now that
I’ve blown some smoke up your gluteous maximus , I have a question for you re. a company you previously covered, i.e., Organovo Holdings (ONVO). What happened to them
this week? Was it all just the “Seeking Alpha” article claiming they were headed to $3?
Did you dump your shares or are you in them for the long run?
Frank White

PS, keep up the great work, it restores my faith in humanity!!!

Larry H.
Guest
0
Larry H.
August 20, 2012 3:11 pm

I bought (onvo) at $1.60 a share and now I’m up 39.16%. I think I will hold for a whileand see where it takes me. Any comments?

Travis Johnson, Stock Gumshoe
Admin
4429
June 30, 2012 8:30 pm

Hi Franklin — thanks for the smoke! I’ve never owned Organovo or looked at them all that closely, though i know they have been teased at least once.
Little biotechs like that are always super-volatile — the pretty similar Tengion keeps threatening to go bankrupt. Haven’t checked to see what might have taken the wid out of Organovo’s sails, but sometimes with these stocks what slows the boat isn’t a fault of the boat but just a lack of blowing from the chattering class.

plattdujour
Member
0
June 30, 2012 10:14 pm

Travis, what is this 15% thing? Is is possible to find out from JB what he’s talking about?
I’m in a 9% Bond Fund right now and even that’s not entirely guaranteed.

Mattie
Guest
0
Mattie
July 2, 2012 2:23 am

Please share your 12 to 15% program with me, JB. my percentage is so low that I refuse to tell you what it is.

drewid
Member
0
drewid
July 6, 2012 4:26 pm

For what it’s worth, insiders have purchased 358k shares of NBS in the past six months and 5 different insiders made purchases on 6/28/12. It’s up nicely today against the run of play. Worth keeping an eye on?

jcurtis595
Member
0
jcurtis595
July 7, 2012 12:05 pm

One email I got today is for the “Online “Bucket” System” by Dr. David Eifrig, M.D., MBA. selling his Retirement Trader at Stansberry Research. Like most of these hypes, there are dozens of supposed customers who made tons of money with no effort in under 60 seconds.
I couldn’t find your Gumshoe report on this. Have you done one? If not, what the hell is this “Bucket” system with options?
Jay Curtis (a big fan of your reports).

jcurtis595
Member
0
jcurtis595
July 7, 2012 12:13 pm

Oh by the way, did I mention our dear doctor wants $3,000 per year for this service, certainly not the cheapest research available.

Jackie Brown
Guest
0
Jackie Brown
July 8, 2012 7:11 pm

pLEASE SHARE JB YOUR l2-l5% guaranteed investment! jackiebelle

Edward Maddox
Guest
0
Edward Maddox
August 8, 2012 6:12 am

JB, your lack of answers simply makes us all think that you just made up your “12 to 15%” and “guaranteed” investments. I, for one, will now discount your statements as a fabrication unless you come up with some answers.

Connie Cody
Guest
0
August 12, 2012 2:26 pm

I have switched all my investments to REITs. Most of them pay double digit divy’s and the share price doesn’t move too much. They are not all just mortgage holdings. I have one which holds only Canadian banks. ZWB.TO. Pays around 7.5%. Good luck to all and many thanks to our Gumshoe.

michael324
Guest
0
michael324
August 12, 2012 2:50 pm

I have been seriously considering getting into REITS. Do you have any particular favorites?

Wayne
Guest
0
Wayne
December 16, 2012 4:20 pm

I have 5000 Shares of AGNC. This stock pays $1.25 Per share Quart. Cost of stock is about $30.50 Nexy Div. is Jan 27.

camporem
Member
0
camporem
August 12, 2012 3:11 pm

Connie I have been wanting to get into REITS, do you have any favorites?

Connie Cody
Guest
0
August 12, 2012 4:24 pm

I own Annaly NLY and Armour ARR. Do a search on Google for REITs an you will get lots of info.

camporem
Member
0
camporem
August 12, 2012 8:59 pm

Thanks for the info, my co-worker told me about annaly I will def check out ARR as well.

Larry H.
Guest
0
Larry H.
August 20, 2012 3:24 pm

Travis,
Any information on Frank Curzio new hot stock that’s 100% American made “Eagle Diesel” which is dubbed as the OPEC crusher and will make us oil and gasoline indpendent. As he states, “it’s 50% cheaper and cleaner than gasoline is today and will replace all gasoline and oil we currently use today. Mighty strong words if you ask me. Or is this just another hype?
Larry H.

montrose
Guest
0
montrose
August 21, 2012 11:21 pm

Larry,
Travis solved couple weeks ago.. stock is … Chart Industries (GTLS) … closed today @ $72.75,,,pricey.. hefty P/E ..38

montrose
Guest
0
montrose
August 21, 2012 11:38 pm

Larry,
Sorry .. There was more to Travis’ article but my reply inadvertenely took-off…there was CleanEnergy, Westport, Cummings…the old Boone Pickens group check this link
http://stockgumshoe.com/reviews/penny-stock-specialist/what-the-heck-is-eagle-diesel-and-will-it-make-us-rich/

Slick Rick
Guest
0
Slick Rick
September 16, 2012 3:33 pm

No guarantee here but DAR a Bio Pharma could explode UP 15% tomorrow 9/17/12. Do your own research ……I KNOW that you will like what you see! DARA is NO BS pumped stock but a legitimate company on the Nasdaq

donna andre
Guest
0
donna andre
October 16, 2012 9:50 am

would love to know the 12 – 15 return stocks.

Robert Newsom
Guest
0
October 16, 2012 12:56 pm

Please , I would like to know more on Bio- Tec Cutting – edge stock with Great Ideas

wpDiscuz